A Comprehensive Review of the Pten/Pi3k/Akt Axis in Multiple Myeloma: From Molecular Interactions to Potential Therapeutic Targets Publisher Pubmed



Alimohammadi M¹ ; Rahimzadeh P² ; Khorrami R³ ; Bonyadi M³ ; Daneshi S⁴ ; Nabavi N⁵ ; Raesi R^{6, 7} ; Farani MR⁸ ; Dehkhoda F⁹ ; Taheriazam A^{10, 11} ; Hashemi M^{10, 12}
Source: Pathology Research and Practice Published:2024

Abstract

Phosphatase and tensin homolog (PTEN), phosphatidylinositol 3-kinase (PI3K), and protein kinase B (Akt) signaling pathways contribute to the development of several cancers, including multiple myeloma (MM). PTEN is a tumor suppressor that influences the PI3K/Akt/mTOR pathway, which in turn impacts vital cellular processes like growth, survival, and treatment resistance. The current study aims to present the role of PTEN and PI3K/Akt/mTOR signaling in the development of MM and its response to treatment. In addition, the molecular interactions in MM that underpin the PI3K/Akt/mTOR pathway and address potential implications for the development of successful treatment plans are also discussed in detail. We investigate their relationship to both upstream and downstream regulators, highlighting new developments in combined therapies that target the PTEN/PI3K/Akt axis to overcome drug resistance, including the use of PI3K and mitogen-activated protein kinase (MAPK) inhibitors. We also emphasize that PTEN/PI3K/Akt pathway elements may be used in MM diagnosis, prognosis, and therapeutic targets. © 2024 Elsevier GmbH